Category: cell

Cell Press dismisses fraud allegations in high-profile genetics papers

Screen Shot 2016-08-03 at 18.54.35Cell Press has dismissed accusations of image manipulation in two well-cited papers. 

In June 2015, we reported that the publisher was investigating anonymous allegations of more than a dozen instances of manipulation of images in the papers published in Cell and Molecular Cell in 1999 and 2001, respectively. 

After assessing the original high-resolution versions of images from the laboratory notebook of Maria Pia Cosma, the first author of both papers, the journals have not found enough evidence to determine that fraud had occurred. 

Here’s the editorial note, issued last week for both papers (and also reported by Leonid Schneider): Continue reading Cell Press dismisses fraud allegations in high-profile genetics papers

Authors retract non-reproducible Cell paper

CellAuthors have retracted a paper from Cell after they were unable to reproduce data in two figures, compromising their confidence in some of the findings.

The authors revisited their experiments after another lab was unable to replicate their data, about proteins that may play a role in lung cancer.

The first author told Nature News in 2013 that the paper may have helped her secure her current position at the Novartis Institutes for Biomedical Research in Massachusetts.

Pulling “Cytohesins are cytoplasmic ErbB receptor activators” appears to be a case of doing the right thing, given the detailed retraction notice:

Continue reading Authors retract non-reproducible Cell paper

Cell Press flags two papers after author confesses to fraud

Screen Shot 2016-04-11 at 8.45.56 PMNormally, when we see disputes over fraud allegations, it’s one author accusing another — but an unusual case at Cell has recently crossed our desk.

The journal has flagged a paper after an author confessed to committing fraud himself — but the corresponding author is disputing that confession, citing concerns about the confessor’s “motives and credibility.”

Independent labs are repeating the experiments to determine if the third author on the paper did, as he so claims, manipulate experiments. In the meantime, Cell and Molecular Cell have issued expressions of concern (EOCs) for two papers on which Yao-Yun Liang was a co-author. The notices cite an inquiry at Baylor College of Medicine, where the work was done, which was inconclusive, and recommended the journals take no action about the papers.

The EOCs are pretty much the same (both journals are published by Cell Press). Here’s the EOC that appears on “PPM1A functions as a Smad phosphatase to terminate TGFbeta signaling,” published in 2006 by Cell and cited 251 times, according to Thomson Reuters Web of Science:

Continue reading Cell Press flags two papers after author confesses to fraud

Stem cell researcher Jacob Hanna’s correction count updated to 10

Jacob Hanna
Jacob Hanna

Thanks to some eagle-eyed readers, we’ve been alerted to some corrections for high profile stem cell scientist Jacob Hanna that we had missed, bringing our count to one retraction and 13 errata on 10 papers.

The problems in the work range from duplications of images, to inadvertent deletions in figures, to failures by his co-authors to disclose funding sources or conflicts of interest. Hanna is the first or last author on 4 of the papers, and one of several on the rest.

First up, a correction to a Cell paper on which Hanna is the first author:

Continue reading Stem cell researcher Jacob Hanna’s correction count updated to 10

Cell Press investigating possible image manipulation in influential yeast genetics paper

cellCell Press is looking into anonymous allegations that a pair of influential papers on gene activation in yeast may contain more than two dozen instances of image manipulation, according to a spokesperson for the journal.

The accusations first appeared in March on PubPeer, where they triggered a small avalanche of comments, including one asserting “unambiguous and repeated examples of data re-use.”

The concerns raised on PubPeer have even sparked an investigation by an institution in Spain, which found no evidence to support the allegations. But not everyone agrees with that verdict.

Continue reading Cell Press investigating possible image manipulation in influential yeast genetics paper

Harvard biofilm paper in Cell breaks down after challenged findings can’t be repeated

CELL_161_4.inddResearchers at Harvard have retracted a Cell paper on biofilm disassembly after they repeated the experiment—following contradictory results from another team—and the new results “can no longer support” the original conclusions.

The 2012 paper, “A Self-Produced Trigger for Biofilm Disassembly that Targets Exopolysaccharide,” describes a factor called norspermidine, produced by the bacteria Bacillus subtilis, that appeared to break down biofilms. The researchers used it to prevent biofilm formation of B. subtilis, Escherichia coli, and Staphylococcus aureus. The paper was cited 72 times, according to Thomson Scientific’s Web of Knowledge.

Two years after it was published, a team from University of Texas Southwestern Medical Center in Dallas and the University of Dundee in the UK contradicted the findings in another Cell publication, “Norspermidine Is Not a Self-Produced Trigger for Biofilm Disassembly.” This time, the authors concluded that norspermidine is not present in B. subtilis biofilms, and actually promotes, rather than breaks down, biofilms. They wrote: Continue reading Harvard biofilm paper in Cell breaks down after challenged findings can’t be repeated

Former Columbia postdoc faked Alzheimer’s research in Cell and Nature

cover_natureRyousuke Fujita, a former Columbia University postdoc who admitted to having faked the findings of a 2011 Cell paper in a retraction notice last year, also faked the results of a 2013 Nature paper, according to a new report from the Office of Research Integrity (ORI).

Fujita’s work, in conjunction with Asa Abeliovich, was widely hailed as a significant step forward, a way to turn skin cells into brain cells. But the story began falling apart when the Cell retraction said that he “acknowledged inappropriately manipulating image panels and data points, as well as misrepresenting the number of repeats performed.”

The ORI’s findings in the case also involve a 2013 Nature paper, “Integrative genomics identifies APOE ε4 effectors in Alzheimer’s disease,” and a paper never published. Fujita, according to the ORI: Continue reading Former Columbia postdoc faked Alzheimer’s research in Cell and Nature

Other shoe drops for MIT cancer researcher Robert Weinberg as Cell retraction appears

cell cloningRobert Weinberg, a prominent cancer scientist whose papers often notch hundreds or thousands of citations, has lost a fourth paper, this time a 2009 publication in Cell.

Journal Genes and Development pulled two of Weinberg’s papers in March, stating that they had retracted the 2009 study because data from several experiments was used in figures that seemed to represent only one. The Genes and Development papers were sunk because the “same analytical methodology was used.”

At the time, the Cell retraction was unavailable, though a spokesperson informed us it was forthcoming. The paper has been cited 482 times, according to Thomson Scientific’s Web of Knowledge.

Now that the notice has landed, here’s why the paper is being retracted: Continue reading Other shoe drops for MIT cancer researcher Robert Weinberg as Cell retraction appears

Award-winning plant researcher correcting several papers critiqued on PubPeer

Olivier Voinnet
Olivier Voinnet

Olivier Voinnet, a researcher at ETH in Zurich and the winner of the 2013 Rössler Prize, is correcting a number of papers following critiques of more than a dozen of his studies on PubPeer.

The work appears in journals including Cell and PNAS. Voinnet’s co-author on several of the papers, David Baulcombe, who is also highly decorated, left this comment on relevant PubPeer entries: Continue reading Award-winning plant researcher correcting several papers critiqued on PubPeer

“I kind of like that about science:” Harvard diabetes breakthrough muddied by two new papers

douglas_melton
Doug Melton

Harvard stem cell researcher Doug Melton got a lot of press last year for research on a hormone he named betatrophin, after its supposed ability to increase production of beta cells, which regulate insulin.

Now, the conclusions from that paper, which has been cited 59 times, according to Thomson Scientific’s Web of Knowledge, have been called into question by research from an independent group, as well as follow-up work from the original team.

The interest was driven by the hormone’s potential as a new treatment for diabetes. In 2013, Melton told the Harvard Gazette that betatrophin could be in clinical trials within three to five years. Here’s Kerry Grens in The Scientist: Continue reading “I kind of like that about science:” Harvard diabetes breakthrough muddied by two new papers